Unknown

Dataset Information

0

A pediatric brain tumor consortium phase II trial of capecitabine rapidly disintegrating tablets with concomitant radiation therapy in children with newly diagnosed diffuse intrinsic pontine gliomas.


ABSTRACT: BACKGROUND:We conducted a phase II study of oral capecitabine rapidly disintegrating tablets given concurrently with radiation therapy (RT) to assess progression-free survival (PFS) in children with newly diagnosed diffuse intrinsic pontine gliomas (DIPG). PATIENTS AND METHODS:Children 3-17 years with newly diagnosed DIPG were eligible. Capecitabine, 650 mg/m2 /dose BID (maximum tolerated dose [MTD] in children with concurrent radiation), was administered for 9 weeks starting the first day of RT. Following a 2-week break, three courses of capecitabine, 1,250 mg/m2 /dose BID for 14 days followed by a 7-day rest, were administered. As prospectively designed, 10 evaluable patients treated at the MTD on the phase I trial were included in the phase II analyses. The design was based on comparison of the PFS distribution to a contemporary historical control (n = 140) with 90% power to detect a 15% absolute improvement in the 1-year PFS with a type-1 error rate, ? = 0.10. RESULTS:Forty-four patients were evaluable for the phase II objectives. Capecitabine and RT was well tolerated with low-grade palmar plantar erythrodyesthesia, increased alanine aminotransferase, cytopenias, and vomiting the most commonly reported toxicities. Findings were significant for earlier progression with 1-year PFS of 7.21% (SE = 3.47%) in the capecitabine-treated cohort versus 15.59% (SE = 3.05%) in the historical control (P = 0.007), but there was no difference for overall survival (OS) distributions (P = 0.30). Tumor enhancement at diagnosis was associated with shorter PFS and OS. Capecitabine was rapidly absorbed and converted to its metabolites. CONCLUSION:Capecitabine did not improve the outcome for children with newly diagnosed DIPG.

SUBMITTER: Kilburn LB 

PROVIDER: S-EPMC5774861 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

A pediatric brain tumor consortium phase II trial of capecitabine rapidly disintegrating tablets with concomitant radiation therapy in children with newly diagnosed diffuse intrinsic pontine gliomas.

Kilburn Lindsay B LB   Kocak Mehmet M   Baxter Patricia P   Poussaint Tina Young TY   Paulino Arnold C AC   McIntyre Christine C   Lemenuel-Diot Annabelle A   Lopez-Diaz Christine C   Kun Larry L   Chintagumpala Murali M   Su Jack M JM   Broniscer Alberto A   Baker Justin N JN   Hwang Eugene I EI   Fouladi Maryam M   Boyett James M JM   Blaney Susan M SM  

Pediatric blood & cancer 20171101 2


<h4>Background</h4>We conducted a phase II study of oral capecitabine rapidly disintegrating tablets given concurrently with radiation therapy (RT) to assess progression-free survival (PFS) in children with newly diagnosed diffuse intrinsic pontine gliomas (DIPG).<h4>Patients and methods</h4>Children 3-17 years with newly diagnosed DIPG were eligible. Capecitabine, 650 mg/m<sup>2</sup> /dose BID (maximum tolerated dose [MTD] in children with concurrent radiation), was administered for 9 weeks st  ...[more]

Similar Datasets

| S-EPMC3280815 | biostudies-literature
| S-ECPF-GEOD-26576 | biostudies-other
| S-EPMC5858123 | biostudies-literature
| S-EPMC5605460 | biostudies-literature
2011-09-20 | E-GEOD-26576 | biostudies-arrayexpress
| S-EPMC10161095 | biostudies-literature
| S-EPMC4279136 | biostudies-literature
2022-12-21 | GSE160249 | GEO
2011-09-21 | GSE26576 | GEO
| S-EPMC9209747 | biostudies-literature